{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-106156","form_type":"8-K","ticker":"MTVA","cik":"0001638287","company_name":"MetaVia Inc.","filed_at":"2026-09-09T13:00:19+00:00","discovered_at":"2026-09-09T13:01:00.469546+00:00","generated_at":"2026-09-09T13:01:05.606161+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"MetaVia reports preclinical DA-1726 tissue distribution: highest in adipose, prolonged retention","bullets":["Preclinical study shows DA-1726-derived radioactivity highest in adipose tissue, with broad distribution and prolonged retention through 144h.","Tissue-to-plasma ratios increased over time; greatest exposure in abdominal, subcutaneous, brown fat, and liver; minimal CNS penetration.","CEO cites Phase 1 data: 48 mg dose achieved mean 9.8 cm waist circumference reduction after 8 weeks (Day 54).","Company expects 16-week topline data in Q4 2026 and 24-week topline results in Q1 2027."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-106156","json":"https://secwatch.observer/filing/0001104659-26-106156.json","markdown":"https://secwatch.observer/filing/0001104659-26-106156.md","text":"https://secwatch.observer/filing/0001104659-26-106156.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1638287/000110465926106156/0001104659-26-106156-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1638287/000110465926106156/mtva-20260909x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-09-09T13:01:05.606161+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}